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Abstract: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant 
deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated 
chemotherapy cycles, and patient characteristics (female gender, younger age, low alcohol 
consumption, history of motion sickness) are the major risk factors for CINV . This review 
provides a detailed description of palonosetron, a second-generation 5-hydroxytryptamine 
3 (5-HT3) receptor antagonist. The chemistry and pharmacology of palonosetron are described, 
as well as the initial and recent clinical trials. Palonosetron has a longer half-life and a higher 
binding affinity than the first-generation 5-HT3 receptor antagonists. Palonosetron has been 
approved for the prevention of acute CINV in patients receiving either moderately or highly 
emetogenic chemotherapy and for the prevention of delayed CINV in patients receiving mod-
erately emetogenic chemotherapy. In recent studies, compared to the first-generation 5-HT3 
receptor antagonists, palonosetron in combination with dexamethasone demonstrated better 
control of delayed CINV in patients receiving highly emetogenic chemotherapy. There were 
no clinically relevant adverse reactions reported in the palonosetron clinical trials which were 
different from the common reactions reported for the 5-HT3 receptor antagonist class. Due to 
its efficacy in controlling both acute and delayed CINV , palonosetron may be very effective in 
the clinical setting of multiple-day chemotherapy and bone marrow transplantation.
Keywords: anti-emetics, chemotherapy-induced nausea and vomiting, serotonin receptor 
antagonists, palonosetron
Introduction
Chemotherapy-induced nausea and vomiting (CINV) is a distressing and common 
adverse event associated with cancer treatment. Patients consistently report that vomit-
ing and nausea are among the most unpleasant and distressing aspects of chemotherapy.1 
Even one or two emetic episodes are associated with a significant deterioration in the 
quality of life, as well as physical and cognitive functioning, and may cause patients 
to delay or refuse potentially curative therapy.2–4
The individual patient risk of CINV is associated with the type of chemotherapy 
administered 5 and specific patient characteristics.6 Agents such as cisplatin and dacar-
bazine have high emetogenic potential with emesis in nearly all patients, while carbo-
platin, anthracyclines, and cyclophosphamide are considered moderately emetogenic 
with emesis in 70% of patients. Etoposide, gemcitabine, and mitoxantrone are of 
low emetogenic potential with emesis in 10% to 70% of patients. Age  50, female 
gender, history of low prior chronic alcohol intake, history of motion sickness, and 
emesis during pregnancy are significant risk factors for CINV .Cancer Management and Research 2009:1 168
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Studies on the prevention of CINV report on 3 distinct 
but related CINV:6 (1) acute CINV (first 24 hours); 
(2) delayed CINV (24 to 120 hours); and (3) overall CINV 
(0 to 120 hours). Although patients can experience CINV for 
longer than 5 days post-chemotherapy, the majority of studies 
have used 120 hours as the measurement period.
Despite the introduction of more effective antiemetic 
agents (5-hydroxytryptamine-3 receptor [5-HT3] antagonists 
and neurokinin-1 [NK-1] receptor antagonists), emesis and 
nausea remain significant complications of chemotherapy. 
This paper reviews the evolving role of palonosetron for 
the prevention and treatment of CINV . The report includes 
a description of the chemistry and the pharmacology of 
palonosetron, a review of the primary clinical trials used for 
the US Food and Drug Administration (FDA) approval of 
palonosetron, as well as a review of recent, new clinical trials 
which may suggest additional clinical indications.
Serotonin (5-HT3) receptor 
antagonists
Serotonin receptors, specifically the 5-HT3 receptors, exist 
in the central nervous system and in the gastrointestinal (GI) 
tract. The first-generation 5-HT3 receptor antagonists, such as 
dolasetron, granisetron, ondansetron, and tropisetron, appear 
to act through both the central nervous system and the GI 
tract via the vagus and splanchnic nerves. The main toxicities 
of these 5-HT3 receptor antagonists consist only of a mild 
headache, mild constipation, and occasional diarrhea.
Table 1 shows the 5-HT3 receptor antagonists currently in 
use. The first-generation serotonin (5-HT3) receptor antago-
nists dolasetron,6 granisetron,6 ondansetron,6 tropisetron,7 
azasetron8 and ramosetron9 are equivalent in efficacy and 
toxicities when used in the recommended doses and compete 
only on an economic basis.10 They have not been associated 
with major toxicities. A prolongation of cardiac conduction 
intervals has been reported for this class of compounds,10–13 
dolasetron being more extensively studied than granisetron 
and ondansetron, but there have been no reported significant 
clinical cardiovascular adverse events.14
The first-generation 5-HT3 receptor antagonists have not 
been as effective against delayed emesis as they are against 
acute CINV .15–20 The available studies show that with cortico-
steroids alone, or combined with either metoclopramide or a 
5-HT3 receptor antagonist in patients receiving cisplatin, the 
incidence of delayed CINV has been reduced, but remains 
a significant problem.21 The first-generation 5-HT3 receptor 
antagonists do not add significant efficacy to that obtained 
by dexamethasone alone in the control of delayed emesis.18 
Hickok et al20 reported that the first-generation 5-HT3s used in 
the delayed period were no more effective than prochlorpera-
zine in controlling nausea. A recent meta-analysis19 showed 
that there was neither clinical evidence nor considerations 
of cost effectiveness to justify using the first-generation 
5-HT3 antagonists beyond 24 hours after chemotherapy for 
the prevention of delayed emesis.
The second-generation 5-HT3 receptor antagonist palo-
nosetron was approved for the prevention of CINV based on 
a number of phase II–III trials22–25 in 2003. Recent studies26 
indicate that it has extended efficacy in controlling delayed 
CINV compared to the first-generation 5-HT3 receptor 
antagonists.
Palonosetron clinical studies
Palonosetron is a 5-HT3 receptor antagonist which has anti-
emetic activity at both central and GI sites.27 In comparison to 
the older 5-HT3 receptor antagonists, it has a higher binding 
affinity to the 5-HT3 receptors (Table 2), a higher potency, 
a significantly longer half-life (approximately 40 hours, 
4 to 10 times longer than that of dolasetron, granisetron, or 
ondansetron) (Table 2), and an excellent safety profile as 
demonstrated in a number of phase II–III studies.22–26,28–32
initial studies
Phase ii
In a dose-finding study,24 a single intravenous dose of palo-
nosetron (0.3–90 µg/kg) was given to 161 patients receiving 
Table 1 Serotonin antagonists and dosage before chemotherapya
Antiemetic Route Dosage
Azasetronb iv 10 mg
Dolasetron iv
po
100 mg or 1.8 mg/kg
100 mg
Granisetron iv
po
Transdermal
10 µg/kg or 1 mg
2 mg (or 1 mg twice daily)
3.1 mg/24 h up to 7 days
Ondansetron iv
po
ODT
0.15 mg/kg or 32 mg
24 mg (highly emetogenic 
chemotherapy agents)
8 mg (moderately emetogenic 
chemotherapy agents
4 mg and 8 mg
Palonosetron iv
po
0.25 mg
0.50 mg
Ramosetronb iv 0.30 mg
Tropisetronb iv or po 5 mg
aThe same doses are used for highly and moderately emetic chemotherapy.
bNot available for use in the US.
Abbreviations: iv, intravenous; ODT, orally disintegrating tablets; po, by mouth.Cancer Management and Research 2009:1 169
Palonosetron for chemotherapy-induced nausea and vomiting Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
cisplatin (70 mg/m2). Approximately 50% of the patients 
who received 3 µg/kg had a complete response (CR) (no 
emesis, no need for rescue) for the first 24 hours post-
chemotherapy, with no significant palonosetron-related 
toxicities. There was no improvement in CR in patients who 
received 3 µg/kg, and patients did not receive corticoste-
roids prior to chemotherapy. This dose-finding study dem-
onstrated that the effective dose was 0.25 mg.24
Phase iii
Eisenberg et al22 reported that 592 patients receiving mod-
erately emetogenic chemotherapy (MEC) were randomized 
to receive a single intravenous dose of dolasetron (100 mg) 
or palonosetron (0.25 mg or 0.75 mg). Sixty-three percent 
of the patients who received 0.25 mg of palonosetron had a 
CR 24 hours post-chemotherapy (acute period), compared 
to 53% of patients who received dolasetron, a clinically 
significant difference, though not statistically superior in 
this trial. CR in the delayed period (24 to 120 hours post-
chemotherapy) was statistically and clinically significantly 
improved in patients who received the 0.25 mg dose of 
palonosetron (54%), compared to the patients who received 
dolasetron (39%). The prevention of nausea (no nausea 
on 4-point Likert scale) was numerically better on days 1 
through 5 and significantly improved on days 2 and 3 of 
the delayed period, as well, in the patients who received 
0.25 mg of palonosetron. The randomization was stratified 
by factors known to significantly affect response rates, 
such as gender, previous chemotherapy exposure, and use 
of corticosteroids.
A similar study of 570 patients receiving MEC was 
randomized to receive a single intravenous dose of palo-
nosetron (0.25 mg or 0.75 mg) or ondansetron (32 mg).23 
CR was significantly better in both the acute and delayed 
period in the patients who received 0.25 mg of palonosetron 
(81%, 74%) compared to ondansetron (69%, 55%). The pre-
vention of nausea was significantly better for palonosetron 
only on days 3 through 5 of the delayed period. There were 
no significant differences in toxicities among the patient 
groups.
In these 2 large studies22,23 in patients receiving MEC, 
CR was improved in the acute and the delayed period for 
the patients who received 0.25 mg of palonosetron alone 
compared to either ondansetron alone (374 patients; acute: 
81.0% versus 68.6%, P = 0.008; delayed: 74.1% versus 
55.1%, P  0.001)23 or dolasetron alone (380 patients; 
acute: 63.0% versus 52.9%, P = 0.049; delayed: 54.0% 
versus 38.7%, P = 0.004).22,23
Dexamethasone was given with the 5-HT3 receptor 
antagonists in only a small number of patients (5%) in only 
one of these studies,22 and it remains to be determined if the 
differences in CR would persist if dexamethasone was used 
in a randomized controlled trial. Importantly, the analysis 
of the Functional Living Index-Emesis (FLIE) data from 
these two randomized trials demonstrated that improved 
control of CINV prevented delayed nausea and vomiting 
from impacting the daily life activities of significantly 
more patients receiving palonosetron than the comparator 
drug.30
In another study, 667 patients receiving highly emeto-
genic chemotherapy (HEC) (cisplatin, 60 mg/m2) received 
one of two doses of palonosetron (0.25 mg or 0.75 mg) 
or ondansetron (32 mg) pre-chemotherapy. Sixty-seven 
percent of the patients in all three study arms also received 
dexamethasone. Single-dose palonosetron was as effective 
as ondansetron in preventing acute CINV and with dexa-
methasone pretreatment, its effectiveness was significantly 
increased over ondansetron throughout the 5-day post-
chemotherapy period.25
In an analysis of the patients in the above studies who 
received repeated cycles of MEC or HEC, Cartmell et al31 
reported that the CR rates for both acute and delayed CINV 
were maintained with the single intravenous doses of palo-
nosetron with or without concomitant corticosteroids.
Based on the above studies, palonosetron was approved 
by the FDA in July, 2003 for the prevention of acute nausea 
and vomiting associated with initial and repeat courses of 
MEC and HEC; and for the prevention of delayed nausea 
and vomiting associated with initial and repeat courses 
of MEC.
Recent studies
Phase ii
Grote et al33 investigated the use of palonosetron in com-
bination with aprepitant, a NK-1 receptor antagonist,21 for 
Table 2 5HT3 receptor antagonists’ binding affinity and plasma 
half-lifea
Drug  pKi [-log(Ki)]  Half-life 
(hours)
Palonosetron 10.45 40
Ondansetron 8.39 4
Granisetron 8.91 9
Dolasetron+ 7.60 7.3
aHalf-life reported for hydrodolasetron, the active metabolite of dolasetron.Cancer Management and Research 2009:1 170
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the prevention of CINV in patients receiving MEC or HEC. 
The multicenter, open-label study evaluated the safety and 
efficacy of a single intravenous dose of palonosetron, 0.25 mg 
on day 1 prior to chemotherapy in combination with three 
consecutive days of oral aprepitant (125 mg on day 1 and 
80 mg on days 2 and 3), and three consecutive days of oral 
dexamethasone (12 mg on day 1 and 8 mg on days 2 and 3). 
Fifty-eight patients were enrolled in the study and 80% 
were women. Breast cancer was the predominant tumor 
type followed by colorectal cancer, lung cancer, and 
malignant lymphoma. Twenty-four of the patients received 
anthracycline/cyclophosphamide combination chemo-
therapy.
A CR was observed in 88% of patients in the first 24 hours 
post-chemotherapy (acute), 78% days 2 to 5 (delayed), and 
78% days 1 to 5 (overall). No nausea was observed in 71% 
of patients in the acute period, 53% in the delayed period, 
and 52% overall. There were no significant adverse events 
during the study. It was concluded that palonosetron with 
dexamethasone and aprepitant was a highly effective regimen 
for patients at risk for CINV .
The comparative efficacy and tolerability of palonosetron 
and ondansetron/dolasetron were assessed in a retrospec-
tive analysis using pooled data from 171 elderly patients 
(age  65 years) with cancer enrolled in 2 randomized 
double-blind, phase III clinical studies comparing single 
intravenous doses of these anti-emetic agents given prior 
to receipt of MEC. The CR was significantly higher in the 
palonosetron group than in the ondansetron/dolasetron group 
in the five days following chemotherapy, suggesting that 
palonosetron is safe and effective in elderly patients with 
cancer receiving emetogenic chemotherapy.34
Hajdenberg et al35 reported the results of another multi-
center, open-label study evaluating the use of palonosetron 
(0.25 mg) and dexamethasone (8 mg) prior to patients 
receiving moderately to highly emetogenic chemotherapy. 
Thirty-two patients completed the study and 62% were 
women. Breast cancer was the predominant tumor type 
followed by colorectal cancer and lung cancer. Carboplatin, 
paclitaxel, doxorubicin, and cyclophosphamide combina-
tion chemotherapy regimens were the most common in this 
study.
A CR was observed in 84% of patients in the first 24 hours 
post-chemotherapy (acute), 59% of patients during days 2 
to 5 (delayed), and 59% days 1 to 5 (overall period). No 
nausea was observed in 78% of patients in the acute period, 
and 50% in the overall period. No significant adverse events 
were reported in the study.
A recent phase II trial of olanzapine and palonosetron 
for the prevention of CINV36 has been reported. Olanzapine 
had been previously shown to be a safe and effective agent 
for the prevention of CINV in chemotherapy naïve cancer 
patients.37 In the phase II trial, the anti-emesis regimen was 
10 mg of oral olanzapine, 0.25 mg of intravenous palonose-
tron, and dexamethasone (20 mg for HEC and 8 mg for MEC) 
on the day of chemotherapy, day 1, and 10 mg/day of oral 
olanzapine alone on days 2 to 4 after chemotherapy. Forty 
chemotherapy-naïve patients (median age 60 years, range 38 
to 84; 22 females; ECOG PS 0, 1) consented to the protocol 
and all were evaluable. The percentage of patients with a CR 
was 100% for the acute period (24 hours post-chemotherapy), 
75% for the delayed period (days 2 to 5 post-chemotherapy), 
and 75% for the overall period (0 to 120 hours) for 
8 patients receiving HEC (cisplatin 70 mg/m2). CR was 
97% for the acute period, 75% for the delayed period, and 
72% for the overall period in 32 patients receiving MEC 
(doxorubicin, 50 mg/m2). In the patients receiving HEC, 
the percentage of patients without nausea (0, scale 0–10, M.D. 
Anderson Symptom Inventory) was 100% in the acute period, 
50% in the delayed period, and 50% in the overall period. 
In patients receiving MEC, the percentage without nausea 
was 100% in the acute period, 78% in the delayed period, and 
78% in the overall period. There were no Grade 3 or 4 toxici-
ties and no significant pain, fatigue, disturbed sleep, memory 
changes, dyspnea, lack of appetite, drowsiness, dry mouth, 
mood changes or restlessness experienced by the patients. CR 
and control of nausea in subsequent cycles of chemotherapy 
(35 patients, cycle 2; 31 patients cycle 3; 23 patients, cycle 4) 
were equal to or greater than cycle one. The combination of 
olanzapine and palonosetron with dexamethasone given only 
on the day of chemotherapy was safe and highly effective 
in controlling acute and delayed CINV in patients receiving 
HEC and MEC.
In a phase II, multicenter, randomized, double-blind, 
parallel, comparative clinical trial, the efficacy and safety 
of palonosetron (0.25 mg) was compared with granisetron 
(3 mg) in Chinese cancer patients receiving HEC. In 
208 patients, palonosetron was not inferior to granisetron in 
preventing acute or delayed chemotherapy-induced vomiting.32 
Adverse events were low among the two groups.
Einhorn et al38 reported on 41 adult men who received 
5 days of cisplatin (20 mg/m2) and were treated with palo-
nosetron, 0.25 mg intravenously on days 1, 3, and 5 and 
dexamethasone, 20 mg iv on days 1 and 2, 8 mg bid orally 
on days 6 and 7, and 4 mg bid orally on day 8. Fifty-one 
percent of the patients had no emetic episodes on days Cancer Management and Research 2009:1 171
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1 to 5 (range 88% day 1 to 68% on day 4) and 83% had 
no emesis on days 6 to 9. The majority of the patients had 
no moderately to severe nausea and did not require rescue 
medications over the nine-day observation period. The 
authors concluded that 3 doses of palonosetron and 5 doses 
of dexamethasone over an 8-day period effectively prevented 
both emesis and significant nausea in the majority of patients 
with germ cell tumors receiving multiple-day cisplatin-based 
chemotherapy. The regimen used appeared to be an improve-
ment over historical controls.
The current recommendation for patients receiving 
multi-day chemotherapy is to give a first-generation 5-HT3 
receptor antagonist plus dexamethasone daily during each 
day of chemotherapy.39 The daily first-generation 5-HT3/
dexamethasone regimen appears to be at least partially effec-
tive in controlling acute CINV , but it is not very effective in 
controlling delayed CINV . The Einhorn et al38 study suggests 
that agents that control both acute and delayed CINV have 
potential as preventative agents in patients receiving multiple-
day chemotherapy.
Musso et al40 used palonosetron as prophylaxis for CINV 
on the first day of chemotherapy and dexamethasone through-
out the entire period of chemotherapy for the prevention 
of CINV in patients receiving multiple-day chemotherapy. 
A second dose of palonosetron was given if breakthrough 
emesis occurred 72 hours after the first administration. 
Compared to a retrospective control group who received 
single-dose ondansetron, dexamethasone throughout, and 
metoclopramide for breakthrough emesis, the palonosetron 
group had less CINV and rescue was more successful.
Phase iii
Saito et al26 conducted a double-blind, double-dummy, ran-
domized, comparative phase III trial in 1143 patients receiv-
ing HEC (cisplatin or the combination of an anthracycline 
and cyclophosphamide). Patients were recruited from 
75 institutions in Japan and were randomly assigned to either 
single-dose palonosetron (0.75 mg) or granisetron (40 µg/kg) 
30 minutes before chemotherapy on day 1. Both groups also 
received dexamethasone, (16 mg iv) on day 1 followed by 
additional doses (8 mg iv for patients receiving cisplatin 
and 4 mg orally for patients receiving an anthracycline and 
cyclophosphamide) on days 2 and 3. Of 555 patients in the 
palonosetron group, 418 (75.3%) had a complete response 
during the first 24 hours (acute period) compared with 
410 of 559 patients (73.3%) in the granisetron group. During 
the delayed period, 315 of 555 patients (56.8%) had a complete 
response in the palonosetron group compared with 249 of 
559 patients (44.5%) in the granisetron group (P  0.0001). 
When administered with dexamethasone, palonosetron pre-
vented CINV which was non-inferior to granisetron in the 
acute period and better than granisetron in the delayed period, 
with a comparable safety profile for the two treatments.
Two randomized, double-blind studies evaluated the 
efficacy and safety of palonosetron versus placebo in prevent-
ing post-operative nausea and vomiting (PONV). A single 
0.075 mg iv dose of palonosetron prior to surgery effectively 
reduced the severity of nausea 24 hours after surgery and 
delayed the time to emesis and treatment failure.41,42 Based 
on these studies, palonosetron was approved by the FDA in 
March, 2008 for the prevention of PONV for up to 24 hours 
following surgery.
Chemistry
Palonosetron HCl is an isoquinolone hydrochloride with 
an empirical formula of C19H24N2O HCl and a molecular 
weight of 332.87. Palonosetron exists as a single isomer and 
its structural formula is shown in Figure 1. It is freely soluble 
in water, soluble in propylene glycol, and slightly soluble in 
ethanol and 2-propanol. Palonosetron injection is a sterile, 
clear, colorless, nonpyrogenic, isotonic, buffered solution 
for intravenous administration.
Pharmacodynamics
Palonosetron is a 5-HT3 receptor antagonist with a high 
binding affinity for this receptor and little or no affinity 
for other receptors. 5-HT3 receptors are located on the 
nerve terminals of the vagus in the periphery and centrally 
in the chemoreceptor trigger zone of the area postrema.21 
Animal studies have demonstrated that chemotherapy agents 
N
O
N
H
H
HCI
Figure 1 Structural formula of palonosetron.Cancer Management and Research 2009:1 172
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produce nausea and vomiting by releasing serotonin from 
the enterochromaffin cells of the small intestine and that 
the released serotonin then activates the 5-HT3 receptors 
located on the vagal afferents to initiate the vomiting reflex. 
Palonosetron demonstrated a 5-HT3 receptor binding affinity 
at least 30-fold higher than other 5-HT3 receptor antagonists 
(Table 2).24,28 Rojas et al43 recently reported that palonose-
tron exhibited allosteric binding and positive cooperativity 
when binding to the 5-HT3 receptor with simple bimolecular 
binding for both granisetron and ondansetron. Palonosetron 
also appeared to affect receptor function. Differences in 
binding and effects on receptor function may explain some 
differences between palonosetron and the first-generation 
5-HT3 receptor antagonists.28
Pharmacokinetics and metabolism
After intravenous dosing of palonosetron in healthy subjects 
and cancer patients, an initial decline in plasma concentra-
tion is followed by a slow elimination from the body. Mean 
maximum plasma concentration and area under the concen-
tration – time curves are generally dose-proportional over 
the dose range of 0.3 to 90 µg/kg in healthy subjects and 
in cancer patients.24 Palonosetron has a volume of distribu-
tion of approximately 8.3 ± 2.5 L/kg and is 62% bound to 
plasma proteins.
Palonosetron is eliminated from the body through renal 
excretion and metabolic pathways. After a single intravenous 
dose of 10 µg/kg  14C palonosetron, approximately 80% 
of the dose was recovered within 144 hours in the urine 
with palonosetron representing approximately 40% of the 
administered dose. The mean terminal elimination half-life 
is approximately 40 hours (Table 2).24,28
Approximately 50% of palonosetron is metabolized to 
form two primary metabolites. Each of these metabolites has 
less than 1% of the 5-HT3 receptor antagonist activity of palo-
nosetron. The metabolic pathways are mediated via multiple 
CYP enzymes, including CYP2D6, and to a lesser extent, 
CYP3A and CYP1A2. Clinical pharmacokinetic parameters 
are not significantly different between poor and extensive 
CYP2D6 metabolizers. In vitro studies have indicated that 
palonosetron is not an inhibitor of CYP1A2, CYP2A6, 
CYP2C9, CYP2D6, CYP2E1, and CYP3A4/5, nor did it 
induce the activity of CYP1A2, CYP2D6, or CYP3A4/5. 
The potential for clinically significant drug interactions with 
palonosetron appears to be low.24,28,29
In controlled clinical trials, palonosetron has been safely 
administered with corticosteroids, analgesics, anti-emetics, 
antispasmodics, and anticholinergic agents.22–26,28,31,33,44,45 
Palonosetron did not inhibit the antitumor activity of five 
chemotherapeutic agents (cisplatin, cyclophosphamide, 
cytarabine, doxorubicin, and mitomycin C) in murine tumor 
models.29
Population pharmacokinetic analysis did not reveal any 
differences between cancer patients 65 years of age and 
younger patients. Mild to moderate renal impairment does 
not significantly affect palonosetron pharmacokinetics and 
hepatic impairment does not significantly affect total body 
clearance of palonosetron compared to healthy patients. 
Therefore, dosage adjustment is not necessary for patients 
with renal or hepatic impairment.28,45
Safety and tolerability
Results from the phase II dose-ranging study and phase III 
comparative studies in patients receiving MEC and HEC 
were the basis for approval of palonosetron by the FDA.22–25,31 
In these studies, patients were exposed to a wide range of 
palonosetron doses, up to 25 times the approved palonose-
tron dose of 0.25 mg. The adverse reactions reported were 
the most common reactions reported for the 5-HT3 receptor 
antagonist class, headache, and constipation. All other reac-
tions occurred at an incidence of 1% in patients treated 
with 0.25 mg of palonosetron.28,46
There were no clinically relevant differences seen among 
palonosetron, ondansetron, or dolasetron in laboratory, 
electrocardiographic, or vital sign changes.28 A clinical 
study in male and female volunteers showed that the cardiac 
profile of palonosetron is the same as placebo. There were 
no electrocardiographic or dose response effects, including 
QTc prolongation, of palonosetron up to a 2.25 mg iv dose, 
a 9-fold safety margin.47 In phase III studies, palonosetron 
was safely administered in 192 patients with pre-existing 
cardiac impairment.28
The safety of palonosetron administered over repeated 
cycles of MEC or HEC was demonstrated in an open-label 
multinational phase III study31,48 which enrolled patients 
who had participated in one of three phase III comparator 
trials.22,23,25
Palonosetron at 3 times the approved dose was well toler-
ated over repeated cycles with no unexpected adverse events. 
There were no clinically relevant differences among cycles, 
and the number of adverse reactions did not increase from 
cycle one to cycle three.
Conclusion
The first-generation 5-HT3 receptor antagonists (dolasetron, 
granisetron, ondansetron, tropisetron, ramosetron, and azasetron) Cancer Management and Research 2009:1 173
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have significant and similar efficacy in the prevention of acute 
CINV for patients receiving MEC and HEC. However, 
these agents do not appear to have significant efficacy in the 
prevention of delayed CINV .
Phase III comparative studies suggest that the use of 
palonosetron alone improves the complete response rate 
of acute and delayed emesis, when compared with the use 
of the first-generation 5-HT3 receptor antagonists alone in 
patients receiving MEC. In combination with dexamethasone, 
palonosetron is effective in controlling acute and delayed 
CINV in patients receiving HEC. With dexamethasone 
pretreatment, single-dose palonosetron was as effective as 
ondansetron and granisetron in preventing acute CINV , and 
with dexamethasone pretreatment, palonosetron’s effective-
ness was significantly increased over ondansetron throughout 
the 5-day post-chemotherapy period and significantly better 
than granisetron in the delayed period.
The complete response rates for palonosetron appear 
to be maintained over repeated cycles of chemotherapy for 
patients receiving either MEC or HEC.
In phase II trials involving patients receiving MEC and 
HEC, palonosetron was combined with dexamethasone and 
aprepitant in one study, with dexamethasone in another study, 
and with dexamethasone and olanzapine in a third study. 
These combinations were safe and highly effective in controll-
ing CINV . The effect of palonosetron on the control of acute 
and delayed CINV in combination with dexamethasone and 
in combination with other anti-emetics in patients receiving 
MEC and HEC and will be the subject of further studies in 
patients receiving emetogenic chemotherapy.
As suggested in 2 phase II clinical trials, palonosetron may 
have marked effectiveness in preventing CINV in patients 
receiving multiple-day chemotherapy due to its demonstrated 
efficacy in preventing both acute and delayed CINV .
In addition to the FDA indications for the prevention of 
acute and delayed CINV (July 2003), palonosetron received 
FDA approval in March 2008 for the prevention of PONV 
based on 2 randomized, double-blind studies.
The safety and tolerability of palonosetron has been 
well documented in multiple, large phase III trials. There 
were no clinically relevant differences seen among palo-
nosetron, ondansetron, or dolasetron in laboratory, electro-
cardiographic, or vital sign changes over multiple cycles 
of chemotherapy. The adverse reactions reported were the 
most common reactions reported for the 5-HT3 receptor 
antagonist class.
The control of nausea in patients receiving MEC and HEC 
remains a significant problem. The current first-generation 
5-HT3 receptor antagonists, while very effective in controlling 
emesis in a large percentage of patients in the initial 24 hours 
post-chemotherapy, nevertheless fail to adequately con-
trol nausea in a significant number of patients. The recent 
palonosetron studies provided some improvement in the 
control of nausea, sometimes to a clinically and statistically 
significant degree.
A recent phase II study using olanzapine in combination 
with palonosetron and dexamethasone showed promise in 
controlling acute and delayed nausea in patients receiving 
MEC and HEC.
Based on initial and recent clinical studies, palonosetron 
is highly effective in controlling acute and delayed CINV 
in patients receiving either MEC or HEC. Compared to the 
first-generation 5-HT3 receptor antagonists, palonosetron has 
equivalent efficacy in controlling acute CINV and appears to 
be more effective in controlling delayed CINV .
Questions that have arisen concerning palonosetron 
include: Does palonosetron differ in mechanism of action 
from the current first-generation 5-HT3 agents? Does the 
higher binding affinity, the longer half-life, or the high potency 
account for the clinical differences between palonosetron and 
the first-generation 5-HT3 receptor antagonists? Does palono-
setron affect 5-HT3 receptors in a different way or in a different 
location than the first-generation 5-HT3 receptor antagonists 
accounting for its apparent efficacy in delayed CINV?
In studies investigating the mechanism of action, palo-
nosetron has been found to exhibit allosteric binding and 
positive cooperativity when binding to the 5-HT3 receptor. 
This is in contrast to the simple bimolecular binding for both 
granisetron and ondansetron. Palonosetron also appeared to 
affect receptor function in these studies. The differences in 
binding and the effects on receptor function may explain the 
differences in the clinical effects between palonosetron and 
the first-generation 5-HT3 receptor antagonists.
The early palonosetron studies demonstrated that 
palonosetron was not inferior to the first generation 5-HT3 
receptor antagonists in controlling acute CINV and may have 
some improved efficacy in controlling delayed CINV . The 
criticisms of these studies were that they were designed as 
noninferiority studies and were done without the use of dexa-
methasone. A recent study has shown that in combination 
with dexamethasone, palonsetron was equivalent to granis-
etron in controlling acute CINV but better than granisetron 
in controlling delayed CINV . The palonosetron dose used in 
this study was 0.75 mg instead of the FDA-approved 0.25 mg 
dose, but previous phase II and III studies have shown these 
two doses to be equivalent.Cancer Management and Research 2009:1 174
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The introduction of 5-HT3 receptor antagonists for the 
prevention of chemotherapy-induced nausea and emesis 
has resulted in a major improvement in supportive care.21 
Treatment guidelines for the prevention of CINV recom-
mended by a number of international groups49–52 suggest 
the use of a 5-HT3 receptor antagonist and dexamethasone 
pre-chemotherapy for the prevention of acute CINV and 
the use of dexamethasone with or without a 5-HT3 receptor 
antagonist following chemotherapy for the prevention of 
delayed nausea and vomiting in patients receiving MEC. 
The guidelines49–52 have also recommended the addition of 
aprepitant,6,21 a NK-1 receptor antagonist, to a 5-HT3 recep-
tor antagonist and dexamethasone pre-chemotherapy and to 
dexamethasone post-chemotherapy for patients receiving 
HEC or receiving the combination of cyclophosphamide and 
doxorubicin, commonly used in patients with breast cancer 
receiving adjuvant chemotherapy.
It should be noted that all four of the 5-HT3 receptor 
antagonists available in the United States are approved 
for the prevention of acute CINV, and palonosetron is the 
only 5-HT3 receptor antagonist approved for the control of 
delayed CINV (in patients receiving MEC). The Multina-
tional Association of Supportive Care in Cancer (MASCC) 
anti-emesis guidelines, and the American Society of Clinical 
Oncology (ASCO) recent anti-emesis guidelines have stated 
that at appropriate dosages, all of the 5-HT3 antagonists 
are interchangeable without preference for any agent. 
The National Comprehensive Cancer Network (NCCN) 
anti-emetic guidelines for the prevention of CINV , have 
now listed palonosetron as the preferred 5-HT3 receptor 
antagonist. Based on the recent studies on palonosetron, it 
appears that there are distinct scientific and clinical differ-
ences between palonosetron and the first-generation 5-HT3 
receptor antagonists. When new guidelines are issued by 
ASCO and MASCC, it is assumed that these differences 
will be included.
Due to its efficacy in both acute and delayed CINV, 
palonosetron has high potential for controlling CINV in the 
settings of multiple-day chemotherapy and bone marrow 
transplantation. Two phase II studies have demonstrated 
the efficacy of palonosetron in controlling CINV in patients 
receiving multiple-day chemotherapy. It is anticipated 
that phase III studies comparing palonosetron to the first-
generation 5-HT3 receptor antagonists will show a marked 
improvement in the control of CINV in patients receiving 
multi-day chemotherapy.
Palonosetron should be further studied for the control 
of nausea and emesis in combination with dexamethasone, 
aprepitant and/or olanzapine. Future research may answer 
if nausea and emesis can be better controlled with these 
combinations. Such studies may not only provide addi-
tional options for the control of acute and delayed CINV, 
but may also provide new information on the mechanism 
of CINV.
Clinicians and other healthcare professionals who are 
involved in administering chemotherapy should be aware 
that studies have strongly suggested that patients experi-
ence more acute and delayed CINV than is perceived by 
practitioners, and patients often do not receive adequate 
prophylaxis. In addition, it is essential to emphasize that the 
current and new agents have been used as prophylaxis for 
acute and delayed CINV and have not been studied for use 
in established CINV .
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